Table 1.
Baseline characteristics of patients in both groups.
| Characteristics | Apatinib
group (n = 58) |
Supportive care group (n = 34) | p value |
|---|---|---|---|
| Age (years)* | 50.9 ± 8.7 | 53.7 ± 7.4 | 0.125 |
| Sex | 0.973 | ||
| Male | 53 (91.4) | 31 (91.2) | |
| Female | 5 (8.6) | 3 (8.8) | |
| Etiology | – | ||
| Hepatitis B | 58 (100) | 34 (100) | |
| Hepatitis C | 0 | 0 | |
| Other | 0 | 0 | |
| Cirrhosis | 0.648 | ||
| Present | 54 (93.1) | 33 (97.1) | |
| Absent | 4 (6.9) | 1 (2.9) | |
| Number of tumors | 0.169 | ||
| 1–5 | 9 (15.5) | 2 (5.9) | |
| >5 | 49 (84.5) | 32 (94.1) | |
| Liver tumor burden | 0.440 | ||
| <50% | 18 (31.0) | 8 (23.5) | |
| ⩾50% | 40 (69.0) | 26 (76.5) | |
| PVTT | 0.480 | ||
| Present | 48 (82.8) | 30 (88.2) | |
| Absent | 10 (17.2) | 4 (11.8) | |
| Extrahepatic spread | 0.206 | ||
| Present | 21 (36.2) | 8 (23.5) | |
| Absent | 37 (63.8) | 26 (76.5) | |
| ECOG | 0.666 | ||
| 0–1 | 55 (94.8) | 31 (91.2) | |
| 2 | 3 (5.2) | 3 (8.8) | |
| AFP (ng/ml) | 0.400 | ||
| <400 | 11 (19.0) | 9 (26.5) | |
| ⩾400 | 47 (81.0) | 25 (73.5) | |
| Child-Pugh class | 0.201 | ||
| A | 49 (84.5) | 25 (73.5) | |
| B | 9 (15.5) | 9 (26.5) | |
| Ascites | 0.068 | ||
| Present | 12 (22.4) | 13 (44.1) | |
| Absent | 46 (77.6) | 21 (55.9) | |
| ALT (U/l) | 49.5 ± 26.8 | 47.4 ± 25.7 | 0.721 |
| GGT (U/l) | 176.2 ± 102.7 | 194.1 ± 128.9 | 0.133 |
| Albumin (g/l) | 35.5 ± 4.0 | 34.1 ± 3.3 | 0.072 |
| Bilirubin (μmol/l) | 18.9 ± 6.4 | 18.4 ± 9.1 | 0.727 |
Data are presented as n (%).
*
Represents the mean ± standard deviation.
AFP, alpha-fetoprotein; ALT, alanine aminotransferase; ECOG, Eastern Cooperative Oncology Group; GGT, γ-glutamyl transpeptidase; PVTT, portal vein tumor thrombosis.